AcuityMD Raises $80M Series C for MedTech Commercial AI

AcuityMD has raised an $80M Series C to build AI around the commercial context that medical-technology companies cannot get from a general-purpose model. The Boston company announced the round on April 21, 2026, with existing investor StepStone Group leading and Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management participating.

The financing brought AcuityMD's reported total funding above $160M and valued the company at $955M. More important than the near-unicorn arithmetic is the infrastructure behind it: AcuityMD is trying to turn a fragmented map of physicians, procedures, facilities, reimbursement, territories, contracts, and sales activity into a working context layer for MedTech commercial teams.

That context is what separates an AI answer that sounds informed from a decision that can survive contact with a hospital, a surgeon, a sales territory, and a changing reimbursement environment. AcuityMD says the new capital will accelerate agentic AI, deepen its proprietary MedTech ontology, and support an expansion beyond commercial functions across the product lifecycle.

What AcuityMD Announced

The $80M Series C was led by StepStone Group, an existing investor. AcuityMD's formal announcement names Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management as participating investors. CEO and co-founder Michael Monovoukas also named HighSage Ventures and Artisanal Ventures in his direct announcement of the financing.

The company reported a $955M valuation and more than $160M in total funding. Its disclosed financing history includes a $7M Seed round in 2021, a $31M Series A in 2022, and a $45M Series B in 2024. AcuityMD said the Series C would fund 3 priorities: accelerate agentic AI for commercial roles, deepen the ontology underpinning its data model, and extend the platform beyond the commercial organization.

Why MedTech Commercial Context Matters

Medical devices do not move through a clean software funnel. A commercial team may need to understand which physician performs a procedure, where that physician operates, how referrals flow, which hospital system controls purchasing, whether reimbursement changed, how a territory was drawn, what a contract allows, and what the company's own CRM says happened last time. Each source can be accurate while the combined decision is still wrong.

AcuityMD was built around that fragmentation. Its platform brings together claims databases, FDA filings, government records, market signals, and each customer's internal commercial data. The company describes the connecting layer as a MedTech ontology: a continuously enriched knowledge graph mapping physicians, facilities, networks, procedures, reimbursement dynamics, and the relationships among them.

AcuityAI sits on top of that foundation. Rather than asking a horizontal model to infer an industry from a prompt, the product combines the ontology with a company's business context and a rep's immediate situation. The intended outputs are operational: a target list, account plan, territory decision, market assessment, or next action that fits the customer and workflow.

The Scale Behind the Round

AcuityMD says it now serves more than 500 MedTech companies, including 16 of the top 20, and has helped customers identify more than $34B in pipeline. The company also says its platform uses an all-payer claims dataset representing more than 330M patients. These are company-reported metrics, but they explain why investors may view the data model as more than a feature attached to an AI interface.

The growth has been building across multiple financing cycles. At the time of its 2024 Series B, AcuityMD reported more than 200 customers, a 10x increase in annual recurring revenue since its Series A, and more than $10B in identified opportunity pipeline. The current platform covers market sizing, territory design, targeting, pipeline management, care journeys, and contracts, with integrations for Salesforce and Snowflake.

That breadth gives AcuityMD a chance to meet commercial users where decisions already happen. It also raises the standard. The more workflows an AI agent can influence, the more important data provenance, permissions, customer-specific rules, and current market context become.

The Investor Logic

General AI models keep getting better at language, synthesis, and tool use. That progress does not automatically give them the private data, industry relationships, or operational definitions needed to make a commercial decision inside a MedTech company. In this market, a fluent answer can still miss the physician, product indication, reimbursement condition, contract term, or account history that changes the action.

StepStone Group partner Hunter Somerville pointed to the depth of AcuityMD's data as an advantage that becomes more valuable as AI capabilities advance. That is the cleanest way to read the round. The investment is not merely a bet that MedTech professionals want another chat interface. It is a bet that vertical context becomes a scarce asset when general intelligence becomes easier to access.

The founding team reflects that mix of commercial and technical focus. Michael Monovoukas, Robert Coe, and Lee Smith founded AcuityMD in 2019. Monovoukas is CEO, Coe is CTO, and Smith is VP of Customer Experience. Their product has moved from sales targeting into a broader commercial platform, and the Series C gives the company capital to test whether its context layer can support agentic work across more roles.

What the $80M Changes

The immediate plan is concrete. AcuityMD intends to expand agents for sales representatives, commercial leadership, and marketing teams while strengthening the ontology underneath them. It also wants to move beyond commercial operations into other functions involved in bringing a medical technology to market.

That second move carries the larger opportunity and the harder execution problem. Commercial targeting can be evaluated against pipeline and account activity. Portfolio strategy, product development, reimbursement planning, and launch sequencing involve more stakeholders, longer timelines, and consequences that are harder to measure. A broader platform must earn trust from each group without pretending that one data model erases the distinctions among them.

AcuityMD has spent 7 years collecting and organizing the market memory surrounding MedTech commercialization. The Series C gives the company more room to turn that memory into action. The next phase will show how far the ontology can travel before every new workflow demands another layer of context.